{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:21:06Z","timestamp":1771676466009,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"North Bristol NHS Trust Research Capability Fund","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12904-017-0255-3","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T07:33:35Z","timestamp":1512718415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the characteristics of patients with mesothelioma who chose active symptom control over chemotherapy as first-line treatment: a prospective, observational, single centre study"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-7754","authenticated-orcid":false,"given":"Anna C.","family":"Bibby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duneesha","family":"De Fonseka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna J.","family":"Morley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Keenan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Edey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick A.","family":"Maskell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,8]]},"reference":[{"issue":"suppl 2","key":"255_CR1","first-page":"ii1","volume":"62","author":"British Thoracic Society Standards Of Care C","year":"2007","unstructured":"British Thoracic Society Standards Of Care C. Bts statement on malignant mesothelioma in the UK, 2007. Thorax. 2007;62(suppl 2):ii1\u2013ii19.","journal-title":"Thorax"},{"issue":"3","key":"255_CR2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","volume":"88","author":"P Beckett","year":"2015","unstructured":"Beckett P, Edwards J, Fennell D, Hubbard R, Woolhouse I, Md P. Demographics, management and survival of patients with malignant pleural mesothelioma in the national lung cancer audit in England and Wales. Lung cancer. 2015;88(3):344\u20138.","journal-title":"Lung cancer"},{"issue":"9","key":"255_CR3","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","volume":"111","author":"A Linton","year":"2014","unstructured":"Linton A, Pavlakis N, O'connell R, Soeberg M, Kao S, Clarke S, Vardy J, Van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in new south wales. Br. J. Cancer. 2014;111(9):1860\u20139.","journal-title":"Br. J. Cancer"},{"issue":"4","key":"255_CR4","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiovasc. Surg. 2012;1(4):491\u20136.","journal-title":"Ann Cardiovasc. Surg"},{"issue":"14","key":"255_CR5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase iii study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003;21(14):2636\u201344.","journal-title":"J. Clin. Oncol"},{"issue":"16_suppl","key":"255_CR6","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1200\/jco.2005.23.16_suppl.7174","volume":"23","author":"J Bloss","year":"2005","unstructured":"Bloss J, Wozniak T, Janne P, Belani C, Keohan M, Ross H, Polikoff J, Mintzer D, Taylor L, Obasaju C. Survival update on a subset of peritoneal mesothelioma (pm) patients in an expanded access program (eap) of pemetrexed (p) alone or combined with cisplatin in the treatment of malignant mesothelioma (mm). J Clin Oncol. 2005;23(16_suppl):7174.","journal-title":"J Clin Oncol"},{"key":"255_CR7","doi-asserted-by":"crossref","unstructured":"Zalcman et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405\u201314.","DOI":"10.1016\/S0140-6736(15)01238-6"},{"issue":"9625","key":"255_CR8","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(08)60727-8","volume":"371","author":"MF Muers","year":"2008","unstructured":"Muers MF, Stephens RJ, Fisher P, Darlison L, Cmb H, Lowry E, Ag N, O'brien M, Peake M, Rudd R, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (ms01): a multicentre randomised trial. Lancet. 2008;371(9625):1685\u201394.","journal-title":"Lancet"},{"key":"255_CR9","unstructured":"Royal College of Physicians of London. National Lung Cancer Audit Pleural Mesothelioma Report 2016 (for the audit period 2014). Available at \nhttps:\/\/www.rcplondon.ac.uk\/projects\/outputs\/national-lung-canceraudit-pleural-mesothelioma-report-2016-audit-period-2014\n\n. Downloaded 06\/12\/17."},{"issue":"6","key":"255_CR10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, Mcfadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am. J. Clin. Oncol. 1982;5(6):649\u201356.","journal-title":"Am. J. Clin. Oncol"},{"key":"255_CR11","doi-asserted-by":"crossref","unstructured":"Bibby AC, Williams K, Smith S, Bhatt N, Maskell NA: What is the role of a specialist regional mesothelioma multidisciplinary team meeting? A service evaluation of one tertiary referral centre in the uk. BMJ Open 2016, 6(9):e012092.","DOI":"10.1136\/bmjopen-2016-012092"},{"issue":"5","key":"255_CR12","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1136\/thx.2007.081430","volume":"63","author":"A Chapman","year":"2008","unstructured":"Chapman A, Mulrennan S, Ladd B, Muers MF. Population based epidemiology and prognosis of mesothelioma in leeds, UK. Thorax. 2008;63(5):435\u20139.","journal-title":"Thorax"},{"issue":"1","key":"255_CR13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajco.12306","volume":"11","author":"SC-H Kao","year":"2015","unstructured":"Kao SC-H, Van Zandwijk N, Clarke S, Vardy J, Lumba S, Tognela A, Ng W. Estimation of an optimal chemotherapy utilization rate for malignant pleural mesothelioma: an evidence-based benchmark for cancer care. Asia Pac J Clin Oncol. 2015;11(1):85\u201392.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"255_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1183\/09031936.00153611","volume":"40","author":"D RAM","year":"2012","unstructured":"RAM D, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur. Respir. J. 2012;40(1):185\u20139.","journal-title":"Eur. Respir. J."},{"key":"255_CR15","doi-asserted-by":"crossref","unstructured":"Kao SH, Clarke S, Vardy J, Corte P, Clarke C, Zandwijk N, Patterns of care for malignant pleural mesothelioma patients compensated by the dust diseases board in new south wales, australia. Intern. Med. J. 2013;43(4):402\u201310.","DOI":"10.1111\/j.1445-5994.2012.02925.x"},{"issue":"4","key":"255_CR16","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1378\/chest.108.4.1122","volume":"108","author":"VW Rusch","year":"1995","unstructured":"Rusch VW. A proposed new international tnm staging system for malignant pleural mesothelioma. From the international mesothelioma interest group. Chest. 1995;108(4):1122\u20138.","journal-title":"Chest"},{"issue":"2","key":"255_CR17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ctrv.2014.12.010","volume":"41","author":"MT Puts","year":"2015","unstructured":"Puts MT, Tapscott B, Fitch M, Howell D, Monette J, Wan-Chow-Wah D, Krzyzanowska M, Leighl NB, Springall E, Alibhai SM. A systematic review of factors influencing older adults\u2019 decision to accept or decline cancer treatment. Cancer Treat. Rev. 2015;41(2):197\u2013215.","journal-title":"Cancer Treat. Rev"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-017-0255-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T07:33:51Z","timestamp":1512718431000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-017-0255-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1186\/s12904-017-0255-3","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"71"}}